How a big biotech’s start-up gamble went wrong
Behind the Money
The History of Illumina's Acquisition of Grail
In 2017, Illumina spun this new cancer screening company out onto its own. They got more than two billion of investment from the likes of Bill Gates and Jeff Bezos. By 2020, the data that Grail was producing for its tests was looking good. And Illumina, Grail's former home, was taking notice. So it actually bought back Grail for $8 billion.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
